Kidney Transplant-Associated Viral Infection Rates and Outcomes in a Single-Centre Cohort.
BKV viremia
CMV viremia
EBV viremia
JCV viremia
kidney transplantation
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
29 10 2022
29 10 2022
Historique:
received:
07
09
2022
revised:
30
09
2022
accepted:
25
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
Opportunistic infections remain a significant cause of morbidity and mortality after kidney transplantation. This retrospective cohort study aimed to assess the incidence and predictors of post-transplant DNA virus infections (CMV, EBV, BKV and JCV infections) in kidney transplant recipients (KTR) at a single tertiary centre and evaluate their impact on graft outcomes. KTR transplanted between 2000 and 2021 were evaluated. Multivariate logistic regression analysis and Cox proportional hazard analyses were used to identify factors associated with DNA virus infections and their impact on allograft outcomes respectively. A sub-analysis of individual viral infections was also conducted to describe the pattern, timing, interventions, and outcomes of individual infections. Data from 962 recipients were evaluated (Mean age 47.3 ± 15 years, 62% male, 81% white). 30% of recipients (288/962) had infection(s) by one or more of the DNA viruses. Individually, CMV, EBV, BKV and JCV viruses were diagnosed in 13.8%. 11.3%, 8.9% and 4.4% of recipients respectively. Factors associated with increased risk of post-transplant DNA virus infection included recipient female gender, higher number of HLA mismatch, lower baseline estimated glomerular filtration rate (eGFR), CMV seropositive donor, maintenance with cyclosporin (rather than tacrolimus) and higher number of maintenance immunosuppressive medications. The slope of eGFR decline was steeper in recipients with a history of DNA virus infection irrespective of the virus type. Further, GFR declined faster with an increasing number of different viral infections. Death-censored graft loss adjusted for age, gender, total HLA mismatch, baseline eGFR and acute rejection was significantly higher in recipients with a history of DNA virus infection than those without infection (adjusted hazard ratio (aHR, 1.74, 95% CI, 1.08-2.80)). In contrast, dialysis-free survival did not differ between the two groups of recipients (aHR, 1.13, 95% CI, 0.88-1.47). Post-transplant DNA viral infection is associated with a higher risk of allograft loss. Careful management of immunosuppression and close surveillance of at-risk recipients may improve graft outcomes.
Sections du résumé
BACKGROUND
Opportunistic infections remain a significant cause of morbidity and mortality after kidney transplantation. This retrospective cohort study aimed to assess the incidence and predictors of post-transplant DNA virus infections (CMV, EBV, BKV and JCV infections) in kidney transplant recipients (KTR) at a single tertiary centre and evaluate their impact on graft outcomes.
METHODS
KTR transplanted between 2000 and 2021 were evaluated. Multivariate logistic regression analysis and Cox proportional hazard analyses were used to identify factors associated with DNA virus infections and their impact on allograft outcomes respectively. A sub-analysis of individual viral infections was also conducted to describe the pattern, timing, interventions, and outcomes of individual infections.
RESULTS
Data from 962 recipients were evaluated (Mean age 47.3 ± 15 years, 62% male, 81% white). 30% of recipients (288/962) had infection(s) by one or more of the DNA viruses. Individually, CMV, EBV, BKV and JCV viruses were diagnosed in 13.8%. 11.3%, 8.9% and 4.4% of recipients respectively. Factors associated with increased risk of post-transplant DNA virus infection included recipient female gender, higher number of HLA mismatch, lower baseline estimated glomerular filtration rate (eGFR), CMV seropositive donor, maintenance with cyclosporin (rather than tacrolimus) and higher number of maintenance immunosuppressive medications. The slope of eGFR decline was steeper in recipients with a history of DNA virus infection irrespective of the virus type. Further, GFR declined faster with an increasing number of different viral infections. Death-censored graft loss adjusted for age, gender, total HLA mismatch, baseline eGFR and acute rejection was significantly higher in recipients with a history of DNA virus infection than those without infection (adjusted hazard ratio (aHR, 1.74, 95% CI, 1.08-2.80)). In contrast, dialysis-free survival did not differ between the two groups of recipients (aHR, 1.13, 95% CI, 0.88-1.47).
CONCLUSION
Post-transplant DNA viral infection is associated with a higher risk of allograft loss. Careful management of immunosuppression and close surveillance of at-risk recipients may improve graft outcomes.
Identifiants
pubmed: 36366504
pii: v14112406
doi: 10.3390/v14112406
pmc: PMC9695979
pii:
doi:
Substances chimiques
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Clin J Am Soc Nephrol. 2008 Mar;3 Suppl 2:S76-86
pubmed: 18309006
Transplant Proc. 2008 Nov;40(9):2927-9
pubmed: 19010150
Transplant Proc. 2004 Sep;36(7):2118-9
pubmed: 15518767
Am J Transplant. 2013 Mar;13(3):656-62
pubmed: 23331474
J Clin Microbiol. 2000 Feb;38(2):712-5
pubmed: 10655372
Transplant Rev (Orlando). 2017 Jan;31(1):55-60
pubmed: 28089555
Einstein (Sao Paulo). 2015 Jan-Mar;13(1):142-8
pubmed: 25993081
Transplant Proc. 2015 Jun;47(5):1429-32
pubmed: 26093735
Transplantation. 2001 Jun 15;71(11):1609-15
pubmed: 11435973
Saudi J Kidney Dis Transpl. 2005 Oct-Dec;16(4):453-97
pubmed: 18202503
Transplant Proc. 2019 Mar;51(2):522-525
pubmed: 30879581
Kidney Int. 2008 Feb;73(3):256-60
pubmed: 17978811
Pediatr Nephrol. 2021 Oct;36(10):3229-3240
pubmed: 33825043
Am J Transplant. 2021 Feb;21(2):669-680
pubmed: 32654412
PLoS One. 2022 Mar 10;17(3):e0265130
pubmed: 35271655
Am J Transplant. 2009 Nov;9(11):2453-8
pubmed: 19843027
Am J Transplant. 2015 Dec;15(12):3143-56
pubmed: 26211927
Transpl Infect Dis. 2021 Apr;23(2):e13483
pubmed: 33012092
J Am Soc Nephrol. 2018 Feb;29(2):680-693
pubmed: 29279304
Toxins (Basel). 2020 Jul 05;12(7):
pubmed: 32635646
Kidney Res Clin Pract. 2018 Dec;37(4):323-337
pubmed: 30619688
Bioessays. 2012 Dec;34(12):1050-9
pubmed: 23012250
Transplantation. 2001 Nov 27;72(10):1587-92
pubmed: 11726814
Clin J Am Soc Nephrol. 2012 Dec;7(12):2058-70
pubmed: 22977217
Clin Transplant. 2019 Apr;33(4):e13516
pubmed: 30849194
Circulation. 2008 Dec 16;118(25):2826-9
pubmed: 19106403
EBioMedicine. 2018 Aug;34:113-121
pubmed: 30072213
Clin Dev Immunol. 2013;2013:926391
pubmed: 23424601
Transplant Proc. 2018 Jan - Feb;50(1):130-136
pubmed: 29407295
J Clin Med. 2020 Apr 22;9(4):
pubmed: 32331309
BMC Geriatr. 2020 Dec 2;20(1):519
pubmed: 33267808
Med Sci Sports Exerc. 2004 Aug;36(8):1290-5
pubmed: 15292734
Clin J Am Soc Nephrol. 2008 Sep;3(5):1526-33
pubmed: 18701615